Dianthus Therapeutics, Inc.
NASDAQDianthus Therapeutics enters the week with a genuinely split picture: short interest is running at 15.6% of the free float — a meaningfully elevated position — yet the lending market is telling a completely different story, with borrow availability loose enough that bears face no structural pressure to cover. The positioning data carries the most interesting tension right now…
Snapshot as of 22 Jun 2026
Dianthus Therapeutics enters the week with a genuinely split picture: short interest is running at 15.6% of the free float — a meaningfully elevated position — yet the lending market is telling a completely different…
Dianthus Therapeutics reports today after market close with short sellers in retreat and analysts broadly constructive — but insider selling from the CFO adds a note of caution to an otherwise positive setup. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DNTH — free to start on ORTEX.
Sign up for free →Open DNTH on ORTEX